{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027730","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.969357+00:00","generated_at":"2026-06-11T14:47:47.442299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ensysce Biosciences Q2 net loss $2.2M; cash $3.8M; IRB approves key PF614 study","bullets":["Net loss for Q2 2023 was $2.2 million versus $7.9 million in Q2 2022; EPS ($0.98) vs ($56.49).","Cash and cash equivalents $3.8 million at June 30, 2023, up from $1.4 million at March 31; increase driven by May 2023 public offering with $7.0 million gross proceeds.","R&D expenses decreased to $1.6 million in Q2 2023 from $5.3 million in Q2 2022 due to timing of clinical studies.","IRB approval received for PF614-201 protocol, a key Phase 3 study; End of Phase 2 meeting with FDA anticipated later this year.","Positive results from oral abuse potential study (PF614-104) and overdose protection Phase 1 study (PF614-MPAR-101) completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027730","json":"https://secwatch.observer/filing/0001493152-23-027730.json","markdown":"https://secwatch.observer/filing/0001493152-23-027730.md","text":"https://secwatch.observer/filing/0001493152-23-027730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223027730/0001493152-23-027730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223027730/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:47:47.442299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e08bda250f79c318c6c07033c9c13f6c1f8ee903","claim":"Ensysce Biosciences, Inc. reported the second quarter of 2023 results: net income Net loss attributable to common stockholders for the second quarter of 2023 was $2.2 million.","evidence_excerpt":"On August 11, 2023, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716947/000149315223027730/0001493152-23-027730-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Net income","value":"Net loss attributable to common stockholders for the second quarter of 2023 was $2.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}